

# Synthesis and antimalarial activity of Baylis-Hillman adducts from substituted 2-chloroquinoline-3-carboxaldehydes

Ejjirothu Srihari<sup>1</sup>, Gangala Siva Kumar<sup>1</sup>, Chebolu Naga Sesha Sai Pavan Kumar<sup>1</sup>, Ratnesh Kumar Seth<sup>2</sup>, Sukla Biswas<sup>2,\*</sup>, Balasubramanian Sridhar<sup>3,\*</sup> and Vaidya Jayathirtha Rao<sup>1,\*</sup>

<sup>1</sup>Organic Chemistry Division-II, Indian Institute of Chemical Technology, Uppal Road, Tarnaka, Hyderabad 500607, India

<sup>2</sup>National Institute of Malaria Research (Indian Council of Medical Research), Sector-8, Dwarka, New Delhi 110077, India

<sup>3</sup>Laboratory of X-ray Crystallography, Indian Institute of Chemical Technology, Uppal Road, Tarnaka, Hyderabad 500607, India

\*Corresponding authors

e-mail: jrao@iict.res.in; suklabiswas@yahoo.com; sshiya@yahoo.com

## Abstract

Various quinoline carboxaldehydes were prepared from corresponding anilides using classical Vilsmeier-Haack reaction conditions and transformed into their Baylis-Hillman adducts. The synthesized Baylis-Hillman adducts were screened for their *in vitro* antimalarial activity against *Plasmodium falciparum*. Most of the compounds out of 21 compounds synthesized and screened exhibited substantial antimalarial activity.

**Keywords:** 2-chloroquinoline-3-carboxaldehyde; antimalarial activity; Baylis-Hillman adducts; crystal structure; Vilsmeier-Haack reaction.

## Introduction


Derivatives of pyridine and its fused analogs are an important class of heterocyclic compounds as a result of their biological activities (Roth and Kleemann, 1988; MDDR, 2004). Quinolines are also known to possess a wide range of biological properties, including antimicrobial, anti-inflammatory, analgesic, antimalarial, anticancer, antiviral, antileishmanial and antitubercular activities (Gantier et al., 1996; Michael, 1997, 2005, 2007; Bilker et al., 1998; Chauhan and Srivastava, 2001; Suryawanshi et al., 2008; Bandgar et al., 2010; Hans et al., 2010; Tomar et al., 2010; Venkatesan and Sumathi, 2010). It is particularly noteworthy that novel quinoline derivatives have recently been reported as possible antimalarial agents (Vlahov et al., 1990; Iwaniuk et al., 2009; Hayat et al., 2011; Kumar et al., 2011b). Continuing our interest in the Baylis-Hillman (BH) reaction (Narender et al., 2006a, 2009;

Ravinder et al., 2009, 2010) and in heterocycles synthesis (Narender et al., 2006b; Srinivas et al., 2009; Kumar et al., 2011a) and with the purpose of exploring biological activity, we synthesized a series of BH adducts, originating from chloroquinoline carboxaldehydes. As part of our study, the BH adducts were screened for their *in vitro* antimalarial activity against *Plasmodium falciparum*.

## Results and discussion

The synthesis of various BH adducts are outlined in Scheme 1. These adducts were selected because of their structural similarity with chloroquine, a known drug used for the control of malaria (Natarajan et al., 2008). The first step in the study was the acetylation of readily available anilines leading to their corresponding anilides. The anilides were subjected to a Vilsmeier-Haack reaction using dimethylformamide (DMF) and phosphorus oxychloride (Scheme 1) to yield the chloroquinoline carbaldehydes (**1a–1k**) with very good yields (Meth-Cohn et al., 1981; Lavergne et al., 1998; Gangadas et al., 2006). The chloroquinoline carbaldehydes were subjected to the BH reaction (Table 1) to produce BH adducts (**2–22**) in excellent yields. Various bases and solvents were employed in conducting the BH reaction (Table 2). The best condition was developed by mixing the starting materials with DABCO at room temperature in solvent free conditions. All BH adducts were characterized by spectroscopic techniques [<sup>1</sup>H nuclear magnetic resonance (NMR), <sup>13</sup>C NMR, infrared (IR) and mass spectrometry]. Compounds **20** (Figure 1) and **4** (Figure 2) were additionally confirmed by single X-ray crystallographic analyses (Bruker, 2001; Sheldrick, 2008).

Thus, 21 BH compounds **2–22** were screened for *in vitro* antimalarial activity (Trager and Jensen, 1976; Biswas, 2001) against a chloroquine sensitive (FDL-J) strain of *P. falciparum* at different doses starting from 50 µg/well to 0.0032 µg/well with five-fold serial dilutions. The doses were kept constant for all compounds so that their activity profiles were comparable with each other. The results, IC<sub>50</sub> and IC<sub>90</sub>, are summarized in Table 3. An overwhelming number of the BH compounds were found to possess excellent anti-*Plasmodium* activity. Adducts **2–12** that contained a nitrile group were more active than adducts **13–22**, which included an ester group (Table 3). This is consistent with our earlier observation (Narender et al., 2005). BH adducts **3**, **14**, **15**, **18** and **19**, which have an alkyl substituent, were less active compared with other compounds suggesting that the lower activity may have been caused by the combined effects of the alkyl substituent and ester end group.



**Scheme 1** Synthesis of Baylis-Hillman adducts from 2-chloroquinoline-3-carboxaldehydes.

## Conclusions

In conclusion, 2-chloroquinoline based BH adducts have been synthesized and characterized. All the compounds were screened for *in vitro* antimalarial activity and found to exhibit substantial antimalarial activity. These molecules will be probed further for their anti-malarial properties.

## Experimental section

All solvents were distilled and dried by standard procedures. Melting points were determined by using capillary melting point apparatus (VMP-AM) and were uncorrected. IR spectra were recorded by using a Thermo Nicolet Nexus 670 FT-IR Spectrometer. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on either a Bruker Avance 300 MHz, Varian Inova 400 MHz or Inova 500 MHz FT spectrometer, using tetramethylsilane as an internal standard (chemical shift values in  $\delta$ , coupling constants J in Hz). HRMS (ESI) data were recorded on a QSTAR XL high-resolution mass spectrometer. Gas chromatography-mass spectrometry (GC-MS) data were recorded on an Agilent 6890 series GC-MS system (column: Varian CP-Sil 8 CB, 5% phenyl, 95% PDMS, 30.0 m $\times$ 250  $\mu$ m $\times$ 0.30  $\mu$ m nominal). Column chromatography was performed by using silica gel (60–120 mesh).

### General procedure for synthesis of Baylis-Hillman (BH) adducts

A mixture of methyl acrylate/acrylonitrile (10.4 mmol) and 1,4-diazabicyclo[2.2.2]octane (DABCO) (3.4 mmol) were combined and stirred at room temperature for 5 min. To this mixture,

2-chloroquinoline-3-carboxaldehyde (5.2 mmol) was added and the mixture was stirred at room temperature for an appropriate length of time (Table 1). The progress of the reaction was monitored by thin layer chromatography (TLC). After completion of the reaction, ethyl acetate (20 ml) was added to the reaction mixture and it was washed with water (4 $\times$ 10 ml). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated *in vacuo*. The crude product was purified by passing through a small pad of silica gel (eluent:hexane:ethyl acetate). The same experimental procedure was adopted for the synthesis of other BH adducts.

**2-[(2-Chloroquinolin-3-yl)(hydroxy)methyl]acrylonitrile (2)** Yield: 97%; sandy brown solid; m.p. 113–115°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  5.81 (s, 1H), 6.11 (s, 1H), 6.12 (s, 1H), 7.58 (t, J=8.3 Hz, 1H), 7.75 (t, J=8.3 Hz, 1H), 7.88 (d, J=8.3 Hz, 1H), 8.00 (d, J=8.3 Hz, 1H), 8.45 (s, 1H), <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  70.0, 117.4, 124.6, 127.3, 128.0, 128.1, 128.9, 131.6, 132.7, 133.9, 137.8, 147.0, 148.4; IR (KBr) 3169, 2924, 2854, 2227, 1727, 1615, 1572, 1491, 1394, 1138, 1074, 1036, 821 cm<sup>-1</sup>; MS (ESI): m/z=245 [M+1]<sup>+</sup>; HRMS: m/z [M+1]<sup>+</sup> calculated for C<sub>13</sub>H<sub>10</sub>ClN<sub>2</sub>O: 245.0481, found: 245.0474.

**2-[(2-Chloro-7-methylquinolin-3-yl)(hydroxy)methyl]acrylonitrile (3)** Yield: 95%; wheatish solid; m.p. 136–138°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  2.58 (s, 3H), 3.27 (s, 1H), 5.80 (s, 1H), 6.10 (s, 1H), 6.11 (s, 1H), 7.40 (d, J=8.3 Hz, 1H), 7.76 (d, J=8.3 Hz, 1H), 7.77 (s, 1H), 8.37 (s, 1H); <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  21.3, 69.5, 116.9, 124.2, 124.9, 126.3, 127.9, 129.6, 131.1, 133.1, 136.9, 141.3, 146.8, 147.8; IR (KBr): 3246, 3056, 2919, 2219, 1626, 1599, 1493, 1396, 1381, 1254, 1140, 1072, 1036, 806 cm<sup>-1</sup>; MS (ESI): m/z=259 [M+1]<sup>+</sup>; HRMS: m/z [M+1]<sup>+</sup> calculated for C<sub>14</sub>H<sub>12</sub>ClN<sub>2</sub>O: 259.0638, found: 259.0627.

**Table 1** Baylis-Hillman adducts synthesized.
































































Entry	Aldehyde	Activated Olef in	BH adducts <sup>a</sup>	Time (h)	Yield (%) <sup>b</sup>
1	 <b>1a</b>		 <b>2</b>	2	97
2	 <b>1b</b>		 <b>3</b>	2.5	95
3	 <b>1c</b>		 <b>4</b>	1.5	94
4	 <b>1d</b>		 <b>5</b>	3	98
5	 <b>1e</b>		 <b>6</b>	1	95
6	 <b>1f</b>		 <b>7</b>	1	97
7	 <b>1g</b>		 <b>8</b>	1	97
8	 <b>1h</b>		 <b>9</b>	0.5	98
9	 <b>1i</b>		 <b>10</b>	2	97
10	 <b>1j</b>		 <b>11</b>	11	93
11	 <b>1k</b>		 <b>12</b>	1	93
12	 <b>1a</b>		 <b>13</b>	4	97

Table 1 (Continued)

Entry	Aldehyde	Activated Olefin	BH adducts <sup>a</sup>	Time (h)	Yield (%) <sup>b</sup>
13				5	91
14				16	80
15				120	89
16				48	91
17				4.5	95
18				8	90
19				6	96
20				30	92
21				36	90

<sup>a</sup>Each reaction was carried out by taking aldehyde (5.2 mmol), activated olefin (10.4 mmol) and DABCO (3.4 mmol) under neat condition; <sup>b</sup>isolated yields of the products.

**2-[[2-Chloro-6-methoxyquinolin-3-yl](hydroxy)methyl]acrylonitrile (4)** Yield: 94%; wheatish solid; m.p. 127–129°C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>+DMSO-*d*<sub>6</sub>) δ 3.91 (s, 1H), 5.61 (d, J=4.8 Hz, 1H), 6.04 (s, 1H), 6.08 (s, 1H), 6.43 (d, J=4.8 Hz, 1H), 7.23 (d, J=2.9 Hz, 1H), 7.33 (dd, J=2.9, 9.7 Hz, 1H), 7.80 (d, J=9.7 Hz, 1H), 8.38 (s, 1H); <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>) δ 55.6, 69.5, 106.1, 116.9, 123.4, 124.2, 128.1, 128.8, 132.2, 133.1, 136.0, 142.4, 145.1, 157.9; IR (KBr): 3546, 3163, 2958, 2915, 2227, 1622, 1589, 1498, 1383, 1340, 1272,

1172, 1092, 1043, 836 cm<sup>-1</sup>; MS (ESI): m/z=275 [M+1]<sup>+</sup>; HRMS: m/z [M+1]<sup>+</sup> calculated for C<sub>14</sub>H<sub>12</sub>ClN<sub>2</sub>O<sub>2</sub>: 275.0587, found: 275.0577.

Crystal data for compound **4**: triclinic, space group *Pi*, a=7.8029 (11) Å, b=9.2884 (13) Å, c=10.5342 (15) Å, α=92.582 (2)°, β=96.257 (2)°, γ=108.614 (2)°, V=716.65 (18) Å<sup>3</sup>, Z=2, D<sub>c</sub>=1.356 Mg m<sup>-3</sup>, μ(Mo Kα)=0.275 mm<sup>-1</sup>, F000=304, T=294(2) K. The total number of measured reflections was 6897. GOF=1.042. CCDC reference number 779379.

**Table 2** Probing reaction conditions in synthesizing the Baylis-Hillman adducts.

S. no.	Base (eq) <sup>a</sup>	Solvent	Time (h) <sup>b</sup>	Yield (%) <sup>c</sup>
1	DABCO (1.0)	Water	24	90
2	DABCO (1.0)	Dichloromethane	26	92
3	DABCO (1.0)	Methanol	48	55
4	DABCO (1.0)	Tetrahydrofuran	15 days	25
5	DABCO (1.0)	1,4-Dioxane	15 days	20
6	DABCO (1.0)	Neat	4	>94
7	DABCO (0.65)	Neat	4	>94
8	DABCO (0.20)	Neat	8	>94
9	Et <sub>3</sub> N (0.65)	Neat	24	<sup>d</sup>
10	Imidazole (0.65)	Neat	24	<sup>d</sup>



<sup>a</sup>2-Chloroquinoline-3-carbaldehyde (1 eq) and methyl acrylate (2 eq) are used; <sup>b</sup>reaction was monitored by TLC; <sup>c</sup>isolated yields; <sup>d</sup>very slow reaction.

**2-[(2-Chloro-6,7-dimethoxyquinolin-3-yl)(hydroxy)methyl]acrylonitrile (5)** Yield: 98%; sandy solid; m.p. 118–120°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 4.00 (s, 3H), 4.02 (s, 3H), 5.79 (s, 1H), 6.11 (s, 1H), 6.14 (s, 1H), 7.05 (s, 1H), 7.25 (s, 1H), 7.29 (s, 1H), 8.23 (s, 1H); <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>) δ 55.8, 55.9, 69.5, 105.8, 106.3, 117.0, 122.6, 124.5, 129.5, 132.7, 135.3, 143.8, 145.2, 150.0, 153.3; IR (KBr): 3535, 3471, 3260, 3108, 2996, 2226, 1621, 1504, 1429, 1249, 1151, 1006, 834 cm<sup>-1</sup>; MS (ESI): *m/z*=305 [M+1]<sup>+</sup>; HRMS: *m/z* [M+1]<sup>+</sup> calculated for C<sub>15</sub>H<sub>14</sub>ClN<sub>2</sub>O<sub>3</sub>: 305.0692, found: 305.0688.

**2-[(2-Chloro-5,8-dimethoxyquinolin-3-yl)(hydroxy)methyl]acrylonitrile (6)** Yield: 95%; light yellow solid; m.p. 156–157°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>+DMSO-*d*<sub>6</sub>) δ 3.99 (s, 1H), 5.67 (s, 1H), 6.06 (s, 1H), 6.08 (s, 1H), 6.80 (d, J=8.5 Hz, 1H), 6.99 (d, J=8.5 Hz, 1H), 8.76 (s, 1H); <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>) δ 55.8, 55.8, 69.5, 105.4, 105.5, 109.9, 116.7, 119.7, 124.2, 131.6, 133.1, 133.1, 138.4, 147.2, 147.9; IR (KBr): 3466, 3107, 2963, 2933, 2223, 1620, 1589, 1480, 1323, 1265, 1115, 1061, 809 cm<sup>-1</sup>; MS (ESI): *m/z*=305 [M+1]<sup>+</sup>; HRMS: *m/z* [M+1]<sup>+</sup> calculated for C<sub>15</sub>H<sub>14</sub>ClN<sub>2</sub>O<sub>3</sub>: 305.0692, found: 305.0698.

**2-[(2-Chloro-6-methylquinolin-3-yl)(hydroxy)methyl]acrylonitrile (7)** Yield: 97%; creamy solid; m.p. 151–152°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>+DMSO-*d*<sub>6</sub>) δ 2.56 (s, 3H), 5.65 (d, J=4.3 Hz, 1H), 6.06 (s, 1H), 6.09 (s, 1H), 6.45 (d, J=4.5 Hz, 1H), 7.56 (dd, J=1.7, 8.6 Hz, 1H), 7.70 (s, 1H), 7.84 (d, J=8.6 Hz, 1H), 8.39 (s, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>+DMSO-*d*<sub>6</sub>) δ 20.6, 69.1, 116.0, 124.4, 126.0, 126.4, 126.7, 130.7, 131.1, 132.2, 135.8, 136.5, 144.8, 146.7; IR (KBr): 3490, 3053, 2938, 2226, 1625, 1591, 1496, 1376, 1339, 1173, 1061, 825 cm<sup>-1</sup>; MS (ESI): *m/z*=259 [M+1]<sup>+</sup>; HRMS: *m/z* [M+1]<sup>+</sup> calculate for C<sub>14</sub>H<sub>12</sub>ClN<sub>2</sub>O: 259.0638, found: 259.0648.

**2-[(2-Chloro-6-isopropylquinolin-3-yl)(hydroxy)methyl]acrylonitrile (8)** Yield: 97%; creamy solid; m.p. 109–110°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>+DMSO-*d*<sub>6</sub>) δ 1.36 (d, J=6.9 Hz, 6H), 3.11 (s, 1H), 5.66 (d, J=4.3 Hz, 1H), 6.05 (s, 1H), 6.07 (s, 1H), 6.36 (d, J=4.7 Hz, 1H), 7.63 (dd, J=1.8, 8.6 Hz, 1H), 7.70 (d, J=1.8 Hz, 1H), 7.89 (d, J=8.6 Hz, 1H), 8.43 (s, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>+DMSO-*d*<sub>6</sub>) δ 23.4, 33.3, 69.4, 116.6,

**Figure 1** ORTEP diagram of compound 20.**Figure 2** ORTEP diagram of compound 4.



**Table 3** Antimalarial activity of Baylis-Hillman adducts 2–22 against CQ-sensitive *P. falciparum* strain (FDL-J).

Compound	Inhibitory activity (µg/ml)		Compound	Inhibitory activity (µg/ml)	
	IC <sub>50</sub>	IC <sub>90</sub>		IC <sub>50</sub>	IC <sub>90</sub>
<b>2</b>	0.80	8.6	<b>13</b>	0.38	8.0
<b>3</b>	4.80	19	<b>14</b>	4.0	21.5
<b>4</b>	0.15	1.6	<b>15</b>	4.2	35
<b>5</b>	0.42	3.3	<b>16</b>	0.38	2.5
<b>6</b>	0.52	9.9	<b>17</b>	0.35	3.4
<b>7</b>	0.32	1.8	<b>18</b>	7.4	51
<b>8</b>	0.58	3.7	<b>19</b>	16.5	60
<b>9</b>	0.64	17	<b>20</b>	0.15	1.65
<b>10</b>	0.50	3.2	<b>21</b>	0.57	12
<b>11</b>	0.13	2.2	<b>22</b>	0.16	1.55
<b>12</b>	2.20	9.1	CQ <sup>a</sup>	0.006	0.026

<sup>a</sup>Choloroquine as standard.

124.0, 124.5, 126.8, 127.3, 130.5, 131.9, 132.3, 136.7, 145.4, 147.0, 147.6; IR (KBr): 3201, 2961, 2925, 2229, 1624, 1587, 1497, 1387, 1310, 1178, 1074, 1040, 830 cm<sup>-1</sup>; MS (ESI): m/z=287 [M+1]<sup>+</sup>; HRMS: m/z [M+1]<sup>+</sup> calculated for C<sub>16</sub>H<sub>16</sub>ClN<sub>2</sub>O: 287.0951, found: 287.0942.

**2-[(2-Chloro-8-methylquinolin-3-yl)(hydroxy)methyl]acrylonitrile (9)** Yield: 98%; creamy solid; m.p. 92–93°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>+DMSO-*d*<sub>6</sub>) δ 2.74 (s, 3H), 5.67 (d, J=4.5 Hz, 1H), 6.06 (s, 1H), 6.08 (s, 1H), 6.42 (d, J=3.7 Hz, 1H), 7.46 (t, J=6.8 Hz, 1H), 7.57 (d, J=6.8 Hz, 1H), 7.75 (d, J=7.9 Hz, 1H), 8.44 (s, 1H); <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>) δ 17.2, 69.5, 116.7, 124.4, 125.9, 126.8, 127.0, 130.7, 131.8, 132.6, 135.3, 137.4, 145.6, 146.9; IR (KBr): 3461, 2919, 2227, 1592, 1481, 1385, 1329, 1172, 1055, 800, 778 cm<sup>-1</sup>; MS (ESI): m/z=259 [M+1]<sup>+</sup>; HRMS: m/z [M+1]<sup>+</sup> calculated for C<sub>14</sub>H<sub>12</sub>ClN<sub>2</sub>O: 259.0638, found: 259.0627.

**2-[(2,7-Dichloroquinolin-3-yl)(hydroxy)methyl]acrylonitrile (10)** Yield: 97%; light yellow solid; m.p. 145–146°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>+DMSO-*d*<sub>6</sub>) δ 5.64 (d, J=4.3 Hz, 1H), 6.08 (s, 1H), 6.11 (s, 1H), 6.52 (m, 1H), 7.56 (dd, J=1.8, 8.8 Hz, 1H), 7.93 (s, 1H), 7.96 (d, J=2.4 Hz, 1H), 8.52 (s, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>+DMSO-*d*<sub>6</sub>) δ 69.4, 116.5, 124.2, 125.4, 126.2, 127.8, 130.0, 132.6, 133.4, 135.6, 137.1, 146.7, 149.2; IR (KBr): 3205, 2924, 2221, 1611, 1478, 1403, 1339, 1259, 1074, 1038, 809 cm<sup>-1</sup>; MS (ESI): m/z=279 [M+1]<sup>+</sup>; HRMS: m/z [M+1]<sup>+</sup> calculated for C<sub>13</sub>H<sub>9</sub>Cl<sub>2</sub>N<sub>2</sub>O: 279.0091, found: 279.0099.

**2-[(2-Chloro-7-fluoroquinolin-3-yl)(hydroxy)methyl]acrylonitrile (11)** Yield: 93%; dark brown solid; m.p. 101–102°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>+DMSO-*d*<sub>6</sub>) δ 5.66 (d, J=4.1 Hz, 1H), 6.05 (s, 1H), 6.09 (s, 1H), 6.41 (d, J=4.3 Hz, 1H), 7.39 (m, 1H), 7.59 (m, 1H), 7.97 (m, 1H), 8.51 (s, 1H); <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>) δ 69.4, 111.1, 111.4, 116.8, 117.5, 117.9, 124.1, 129.8, 129.8, 131.0, 131.1, 131.6, 133.1, 137.3, 147.3, 147.5, 149.2, 161.5, 164.8; IR (KBr): 3483, 3069, 2921, 2224, 1623, 1569, 1491, 1336, 1209, 1122, 1061, 1029, 863, 809 cm<sup>-1</sup>; MS (ESI): m/z=263 [M+1]<sup>+</sup>; HRMS: m/z [M+1]<sup>+</sup> calculated for C<sub>13</sub>H<sub>9</sub>ClFN<sub>2</sub>O: 263.0387, found: 263.0396.

**2-[(2,7-Dichloro-6-fluoroquinolin-3-yl)(hydroxy)methyl]acrylonitrile (12)** Yield: 93%; light yellow solid; m.p. 159–120°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 5.79 (s, 1H), 6.14 (s, 1H), 6.16 (s, 1H), 7.25 (s, 1H), 7.62 (d, J=6.8 Hz, 1H), 8.11 (d, J=6.8 Hz, 1H), 8.40 (s, 1H); <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>) δ 69.4, 113.0, 113.3, 116.8, 123.8, 124.7, 125.0, 126.5, 126.6, 129.3, 133.4, 133.7, 136.8, 136.9, 143.4, 148.5, 148.6, 153.5, 156.8; IR (KBr): 3257, 3065, 2922, 2225, 1598, 1482, 1347, 1226, 1073, 1041, 874, 816 cm<sup>-1</sup>; MS (ESI): m/z=297 [M+1]<sup>+</sup>; HRMS: m/z [M+1]<sup>+</sup> calculated for C<sub>13</sub>H<sub>8</sub>Cl<sub>2</sub>FN<sub>2</sub>O: 296.9997, found: 296.9989.

**Methyl 2-[(2-chloroquinolin-3-yl)(hydroxy)methyl]acrylate (13)** Yield: 97%; creamy solid; m.p. 124–126°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 3.62 (d, J=4.9 Hz, 1H), 3.81 (s, 3H), 5.57 (s, 1H), 5.99 (d, J=4.5 Hz, 1H), 6.35 (s, 1H), 7.55 (t, J=7.1 Hz, 1H), 7.71 (t, J=7.1 Hz, 1H), 7.84 (d, J=8.1 Hz, 1H), 8.00 (d, J=8.5 Hz, 1H), 8.36 (s, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 52.2, 69.0, 127.1, 127.2, 127.6, 127.7, 128.0, 130.5, 132.6, 137.0, 140.1, 147.0, 149.2, 166.7; IR (KBr): 3537, 3219, 3060, 2951, 1715, 1625, 1590, 1298, 1145, 1060, 1030, 758 cm<sup>-1</sup>; MS (ESI): m/z=278 [M+1]<sup>+</sup>; HRMS: m/z [M+1]<sup>+</sup> calculated for C<sub>14</sub>H<sub>13</sub>ClNO<sub>3</sub>: 278.0583, found: 278.0592.

**Methyl 2-[(2-chloro-7-methylquinolin-3-yl)(hydroxy)methyl]acrylate (14)** Yield: 91%; creamy solid; m.p. 95–97°C; <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>) δ 2.56 (s, 3H), 3.18 (s, 1H), 3.71 (s, 1H), 5.73 (s, 1H), 5.94 (s, 1H), 6.34 (s, 1H), 7.37 (d, J=8.1 Hz, 1H), 7.69 (s, 1H), 7.74 (d, J=8.1 Hz, 1H), 8.22 (s, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 21.8, 52.1, 68.8, 125.1, 126.9, 127.3, 127.4, 129.3, 131.8, 136.7, 140.3, 141.1, 147.1, 149.2, 166.6; IR (KBr): 3284, 2948, 2920, 1725, 1624, 1326, 1256, 1133, 1035, 808 cm<sup>-1</sup>; MS (ESI): m/z=292 [M+1]<sup>+</sup>; HRMS: m/z [M+1]<sup>+</sup> calculated for C<sub>15</sub>H<sub>15</sub>ClNO<sub>3</sub>: 292.0740, found: 292.0745.

**Methyl 2-[(2-chloro-6-methoxyquinolin-3-yl)(hydroxy)methyl]acrylate (15)** Yield: 80%; creamy solid; m.p. 105–106°C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 3.54 (s, 1H), 3.80 (s, 3H), 3.91 (s, 3H), 5.57 (s, 1H), 5.96 (s, 1H), 6.34 (s, 1H), 7.06 (d, J=1.9 Hz, 1H), 7.33 (dd, J=1.9, 9.7 Hz, 1H), 7.87 (d, J=9.7 Hz, 1H), 8.22 (s, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 52.1, 55.5, 68.9, 105.1, 123.1, 127.5, 128.1, 129.2, 132.8, 135.7, 140.2, 142.8, 146.5, 158.1, 166.6; IR (KBr): 3311, 2956, 2832, 1722, 1624, 1497, 1328, 1257, 1153, 1032, 823 cm<sup>-1</sup>; MS (ESI): m/z=308 [M+1]<sup>+</sup>; HRMS: m/z [M+1]<sup>+</sup> calculated for C<sub>15</sub>H<sub>15</sub>ClNO<sub>4</sub>: 308.0689, found: 308.0695.

**Methyl 2-[(2-chloro-6,7-dimethoxyquinolin-3-yl)(hydroxy)methyl]acrylate (16)** Yield: 89%; sandy solid; m.p. 133–135°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 3.64 (d, J=3.0 Hz, 1H), 3.79 (s, 3H), 3.98 (s, 3H), 4.00 (s, 3H), 5.59 (s, 1H), 5.94 (d, J=3.0 Hz, 1H), 6.34 (s, 1H), 7.01 (s, 1H), 7.28 (s, 1H), 8.14 (s, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 52.1, 56.0, 56.1, 105.0, 106.7, 122.7, 127.3, 130.4, 135.1, 140.3, 144.1, 146.8, 150.0, 153.2, 166.7; IR (KBr): 3391, 3008, 2920, 1713, 1631, 1503, 1247, 1145, 1006, 849 cm<sup>-1</sup>; MS (ESI): m/z=338 [M+1]<sup>+</sup>; HRMS: m/z [M+1]<sup>+</sup> calculated for C<sub>16</sub>H<sub>17</sub>ClNO<sub>5</sub>: 338.0795, found: 338.0791.

**Methyl 2-[(2-chloro-5,8-dimethoxyquinolin-3-yl)(hydroxy)methyl]acrylate (17)** Yield: 91%; carrot orange solid; m.p. 155–157°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 3.75 (s, 1H), 3.80 (s, 3H), 3.96 (s, 3H), 4.01 (s, 3H), 5.54 (s, 1H), 6.00 (s, 1H), 6.34 (s, 1H), 6.72 (d, J=8.3 Hz, 1H), 6.92 (d, J=8.3 Hz, 1H), 8.69 (s, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 52.1, 55.6, 55.9, 69.0, 104.3, 108.2, 120.4, 127.5, 132.1, 132.3, 139.0, 140.2, 148.1, 148.5, 149.0,

166.7; IR (KBr): 3421, 3003, 2934, 1721, 1618, 1475, 1434, 1371, 1266, 1116, 1096, 802  $\text{cm}^{-1}$ ; MS (ESI):  $m/z=338$   $[\text{M}+1]^+$ ; HRMS:  $m/z$   $[\text{M}+1]^+$  calculated for  $\text{C}_{16}\text{H}_{17}\text{ClNO}_3$ : 338.0795, found: 338.0782.

**Methyl 2-[(2-chloro-6-methylquinolin-3-yl)(hydroxy)methyl]acrylate (18)** Yield: 95%; creamy solid; m.p. 118–119°C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  2.53 (s, 3H), 3.72 (d,  $J=5.2$  Hz, 1H), 3.79 (s, 3H), 5.57 (s, 1H), 5.96 (d,  $J=4.5$  Hz, 1H), 6.34 (s, 1H), 7.51 (dd,  $J=8.3, 2.2$  Hz, 1H), 7.58 (s, 1H), 7.86 (d,  $J=8.3$  Hz, 1H), 8.24 (s, 1H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  21.5, 52.2, 69.2, 126.6, 127.1, 127.6, 127.7, 132.4, 132.8, 136.3, 137.2, 140.1, 145.6, 148.3, 166.7; IR (KBr): 3452, 3000, 2951, 2920, 1699, 1624, 1333, 1257, 1144, 1061, 1035, 821  $\text{cm}^{-1}$ ; MS (ESI):  $m/z=292$   $[\text{M}+1]^+$ ; HRMS:  $m/z$   $[\text{M}+1]^+$  calculated for  $\text{C}_{15}\text{H}_{15}\text{ClNO}_3$ : 292.0740, found: 292.0751.

**Methyl 2-[(2-chloro-6-isopropylquinolin-3-yl)(hydroxy)methyl]acrylate (19)** Yield: 90%; semi solid;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  1.35 (d,  $J=6.9$  Hz, 6H), 3.09 (s, 1H), 3.46 (d,  $J=4.7$  Hz, 1H), 3.82 (s, 3H), 5.57 (s, 1H), 5.98 (d,  $J=3.4$  Hz, 1H), 6.35 (s, 1H), 7.61 (d,  $J=8.5$  Hz, 1H), 7.63 (s, 1H), 7.92 (d,  $J=8.5$  Hz, 1H), 8.30 (s, 1H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  23.7, 23.8, 34.0, 52.2, 69.2, 123.9, 127.2, 127.6, 127.9, 130.5, 132.3, 136.7, 140.1, 145.9, 148.0, 148.3, 166.8; IR (Neat): 3383, 2960, 1721, 1592, 1495, 1436, 1262, 1145, 1054, 1032, 830  $\text{cm}^{-1}$ ; MS (ESI):  $m/z=320$   $[\text{M}+1]^+$ ; HRMS:  $m/z$   $[\text{M}+1]^+$  calculated for  $\text{C}_{17}\text{H}_{19}\text{ClNO}_3$ : 320.1053, found: 320.1061.

**Methyl 2-[(2-chloro-8-methylquinolin-3-yl)(hydroxy)methyl]acrylate (20)** Yield: 96%; light yellow solid; m.p. 110–111°C;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  2.7 (d,  $J=4.8$  Hz, 3H), 3.50 (d,  $J=3.9$  Hz, 1H), 3.81 (d,  $J=6.8$  Hz, 3H), 5.58 (s, 1H), 6.00 (s, 1H), 6.35 (d,  $J=3.9$  Hz, 1H), 7.42 (q,  $J=6.8, 7.8$  Hz, 1H), 7.54 (t,  $J=6.8$  Hz, 1H), 7.67 (t,  $J=8.7$  Hz, 1H), 8.31 (d,  $J=6.8$  Hz, 1H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  29.5, 52.1, 68.9, 125.5, 126.8, 127.0, 127.5, 130.4, 132.2, 136.1, 137.0, 140.2, 146.2, 148.1, 166.7; IR (KBr): 3497, 2954, 2922, 1704, 1631, 1436, 1292, 1155, 1084, 1049, 762  $\text{cm}^{-1}$ ; MS (ESI):  $m/z=292$   $[\text{M}+1]^+$ ; HRMS:  $m/z$   $[\text{M}+1]^+$  calculated for  $\text{C}_{15}\text{H}_{15}\text{ClNO}_3$ : 292.0740, found: 292.0743.

Crystal data for compound **20**: orthorhombic, space group *Pbca*,  $a=8.7662$  (4) Å,  $b=14.9431$  (7) Å,  $c=21.3508$  (10) Å,  $\alpha=90$  (1)°,  $\beta=90$  (1)°,  $\gamma=90$  (1)°,  $V=2796.8$  (2) Å<sup>3</sup>,  $Z=8$ ,  $D_c=1.386$  Mg m<sup>-3</sup>,  $\mu(\text{Mo K}\alpha) = 0.279$  mm<sup>-1</sup>,  $F(000)=1216$ ,  $T=294$ (2) K. Total number of measured reflections was 25 010.  $GOF=1.087$ . CCDC reference number 779378.

**Methyl 2-[(2,7-dichloroquinolin-3-yl)(hydroxy)methyl]acrylate (21)** Yield: 92%; creamy solid; m.p. 102–104°C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3+\text{DMSO}-d_6$ )  $\delta$  3.74 (s, 1H), 5.73 (d,  $J=4.5$  Hz, 1H), 5.84 (d,  $J=4.5$  Hz, 1H), 5.95 (d,  $J=4.9$  Hz, 1H), 6.35 (d,  $J=4.9$  Hz, 1H), 7.53 (s, 1H), 7.87 (d,  $J=4.7$  Hz, 1H), 7.94 (s, 1H), 8.32 (d,  $J=4.7$  Hz, 1H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{DMSO}-d_6$ )  $\delta$  51.8, 67.0, 125.5, 126.1, 126.4, 127.9, 130.0, 135.0, 135.1, 136.9, 141.5, 146.4, 150.5, 165.5; IR (KBr): 3433, 2959, 1704, 1613, 1479, 1328, 1260, 1068, 1030, 805  $\text{cm}^{-1}$ ; MS (ESI):  $m/z=312$   $[\text{M}+1]^+$ ; HRMS:  $m/z$   $[\text{M}+1]^+$  calculated for  $\text{C}_{14}\text{H}_{12}\text{Cl}_2\text{NO}_3$ : 312.0194, found: 312.0203.

**Methyl 2-[(2-chloro-7-fluoroquinolin-3-yl)(hydroxy)methyl]acrylate (22)** Yield: 90%; pale yellow solid; m.p. 118–120°C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  3.81 (s, 4H), 5.57 (s, 1H), 5.96 (s, 1H),

6.35 (s, 1H), 7.34 (m, 1H), 7.62 (dd,  $J=2.2, 9.6$  Hz, 1H), 7.84 (m, 1H), 8.35 (s, 1H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  52.2, 69.1, 112.9, 112.2, 117.5, 117.9, 124.1, 127.7, 129.8, 129.9, 130.3, 132.0, 136.9, 140.0, 147.9, 150.5, 161.9, 165.3, 166.7; IR (KBr): 3537, 3248, 2948, 1714, 1495, 1336, 1209, 1061, 1030, 862, 813  $\text{cm}^{-1}$ ; MS (ESI):  $m/z=296$   $[\text{M}+1]^+$ ; HRMS:  $m/z$   $[\text{M}+1]^+$  calculated for  $\text{C}_{14}\text{H}_{12}\text{ClFNO}_3$ : 296.0489, found: 296.0491.

## General procedure for the synthesis of substituted 2-chloroquinoline-3-carboxaldehydes

*N,N*-Dimethylformamide (0.13 mol) was cooled to 0°C (ice-salt bath) in a round bottom flask and phosphorus oxychloride (0.35 mol) was added dropwise with stirring under nitrogen atmosphere. Acetanilide (0.05 mol) was added to the solution and after 5 min the solution was heated under reflux for appropriate time. The progress of the reaction was monitored by TLC. Upon completion of the reaction, the reaction mixture was cooled to room temperature and then slowly added to ice-cold water (300 ml), stirred for 30 min at 0–10°C. The precipitated aldehyde was filtered and washed with water (4×50 ml).

## Procedure for synthesis of 2-chloro-6-isopropylquinoline-3-carboxaldehyde (1g)

*N,N*-Dimethylformamide (141.2 mmol, 10.9 ml) was cooled to 0°C in a dry round bottom flask and phosphoryl chloride (396.6 mmol, 36.3 ml) was added dropwise with stirring. To this solution, acetanilide (56.5 mmol, 10 g) was added and after 5 min the solution was heated under reflux at 75°C for 15 h. The progress of the reaction was monitored by TLC. Upon completion of the reaction, the reaction mixture was cooled to room temperature and then slowly poured into ice-cold water (300 ml) with constant stirring at 0–10°C. 2-Chloro-6-isopropyl-3-quinoline-carboxaldehyde was filtered off and washed with water. Yield: 81%; creamy solid; m.p. 108–110°C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  1.36 (d,  $J=6.8$  Hz, 6H), 3.11 ( $J=6.8$  Hz, 1H), 7.74 (s, 1H), 7.75 (d,  $J=8.3$  Hz, 1H), 7.98 (d,  $J=8.3$  Hz, 1H), 8.67 (s, 1H), 10.55 (s, 1H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  23.5, 33.9, 125.6, 126.1, 126.5, 128.3, 133.6, 139.8, 148.4, 148.9, 149.2, 189.1; IR (KBr): 3047, 2961, 2869, 1695, 1579, 1427, 1376, 1041, 847, 775  $\text{cm}^{-1}$ ; GC-MS  $m/z$ : 233  $[\text{M}^+]$ .

## Biological activity

The anti-*Plasmodium* activity was checked using a well-adapted *P. falciparum* culture line (FDL-J) following the published method (Biswas, 2001). The parasite isolate was collected from a patient reported with symptomatic malaria in a local clinic of Delhi in 2007. The parasite was adapted and maintained *in vitro* by candle-jar technique (Trager and Jensen, 1976). The assay was done in synchronous culture with ring form at 5% haematocrit containing 1% parasitaemia in 96-well flat bottom tissue culture plate. Compounds were dosed in wells in duplicate at concentrations starting from 50  $\mu\text{g}$ /well onwards with five-fold serial dilutions up to 0.0032  $\mu\text{g}$ /well. The volume of culture per well was kept at 200  $\mu\text{l}$  including media, drug and parasite inoculum. The parasite culture only in enriched media was taken as a control. Chloroquine was used as the reference antimalarial for comparison. The assay was done for 48 h to determine the activity of various compounds in total parasite growth. The growth of the parasite in each well was monitored microscopically

in Giemsa-stained smears by counting the total number of parasites per 5000 red blood cells. Percent parasite growth inhibition was calculated by the formula:  $(1 - N_t/N_c) \times 100$ , where  $N_t$  and  $N_c$  represent the number of parasites in the test and control wells, respectively. Inhibitory concentrations at 50% ( $IC_{50}$ ) and 90% ( $IC_{90}$ ) were calculated.

## Acknowledgements

The authors thank Director, IICT and Head, Organic-II Division for the encouragement. This work is the Main Lab Project of IICT. ESR, GSK and CHNSSP thank CSIR, New Delhi for the research fellowships.

## References

- Bandgar, B. P.; Gawande, S. S.; Bodade, R. G.; Totre, J. V.; Khobragade, C. N. Synthesis and biological evaluation of simple methoxylated chalcones as anticancer, anti-inflammatory and antioxidant agents. *Bioorg. Med. Chem.* **2010**, *18*, 1364–1370.
- Bilker, O.; Lindo, V.; Panico, M.; Etiene, A. E.; Paxton, T.; Dell, A.; Rogers, M.; Sinden, R. E.; Morris, H. R. Identification of xanthurenic acid as the putative inducer of malaria development in the mosquito. *Nature* **1998**, *392*, 289–292.
- Biswas, S. In vitro antimalarial activity of azithromycin against chloroquine sensitive and chloroquine resistant *Plasmodium falciparum*. *J. Postgrad. Med.* **2001**, *47*, 240–243.
- Bruker. *SAINT (Version 6.28a) & SMART (Version 5.625)*. Bruker AXS Inc: Madison, Wisconsin, USA, **2001**.
- Chauhan, P. M. S.; Srivastava, S. K. Present trends and future strategy in chemotherapy of malaria. *Curr. Med. Chem.* **2001**, *8*, 1535–1542.
- Gangadas, B.; Narender, P.; Bharath Kumar, S.; Ravinder, M.; Ananda Rao, B.; Ramesh, Ch.; China Raju, B.; Jayathirtha Rao, V. Facile and selective synthesis of chloronicotinaldehydes by the Vilsmeier reaction. *Tetrahedron* **2006**, *62*, 8398–8403.
- Gantier, J. C.; Fournet, A.; Munos, M. H.; Hocquemiller, R. The effect of some 2-substituted quinolines isolated from *Galipea longiflora* on *Plasmodium vinckei petteri* infected mice. *Planta Med.* **1996**, *62*, 285–286.
- Hans, R. H.; Guantai, E. M.; Lategan, C.; Smith, P. J.; Wan, B.; Franzblau, S. G.; Gut, J.; Rosenthal, P. J.; Chibale, K. Synthesis, antimalarial and antitubercular activity of acetylenic chalcone. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 942–944.
- Hayat, F.; Moseley, E.; Salahuddin, A.; Van Zyl, R. L.; Azam, A. Antiprotozoal activity of chloroquinoline based chalcones. *Eur. J. Med. Chem.* **2011**, *46*, 1897–1905.
- Iwaniuk, D. P.; Whetmore, E. D.; Rosa, N.; Ekoue-kovi, K.; Alumasa, J.; De Dios, A. C.; Roepe, P. D.; Wolf, C. Synthesis and antimalarial activity of new chloroquine analogues carrying a multifunctional linear side chain. *Bioorg. Med. Chem.* **2009**, *17*, 6560–6566.
- Kumar, Ch. N. S. S. P.; Parida, D. K.; Santhoshi, A.; Kota, A. K.; Sridhar, B.; Jayathirtha Rao, V. Synthesis and biological evaluation of tetrazole containing compounds as possible anticancer agents. *Med. Chem. Comm.* **2011a**, *2*, 486–492.
- Kumar, A.; Srivastava, K.; Raja Kumar, S.; Siddiqi, M. I.; Puri, S. K.; Sexana, J. K.; Chauhan, P. M. S. 4-Anilinoquinoline triazines: a novel class of hybrid antimalarial agents. *Eur. J. Med. Chem.* **2011b**, *46*, 676–690.
- Lavergne, O.; Lesueur-Ginot, L.; Pla Rodas, F.; Kasprzyk, P. G.; Pommier, J.; Demarquay, D.; Prevost, G.; Ulibarri, G.; Rolland, A.; Schiano-Liberatore, A. M.; et al. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. *J. Med. Chem.* **1998**, *41*, 5410–5419.
- MDDR: MDL Drug Data Registry, by MDL Informations Systems, Inc.: San Leandro, California, USA, **2004**.
- Meth-Cohn, O.; Narine, B.; Tarnowski, B. A versatile new synthesis of quinolines and related fused pyridines. Part 5. The synthesis of 2-chloroquinoline-3-carbaldehydes. *J. Chem. Soc., Perkin Trans. 1* **1981**, 1520–1529.
- Michael, J. P. Quinoline, quinazoline and acridone alkaloids. *Nat. Prod. Rep.* **1997**, *14*, 605–618.
- Michael, J. P. Quinoline, quinazoline and acridone alkaloids. *Nat. Prod. Rep.* **2005**, *22*, 627–646.
- Michael, J. P. Quinoline, quinazoline and acridone alkaloids. *Nat. Prod. Rep.* **2007**, *24*, 223–246.
- Narender, P.; Srinivas, U.; Gangadasu, B.; Biswas, S.; Jayathirtha Rao, V. Anti-malarial activity of Baylis–Hillman adducts from substituted 2-chloronicotinaldehydes. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 5378–5381.
- Narender, P.; Gangadasu, B.; Ravinder, M.; Srinivas, U.; Swamy, G. Y. S. K.; Ravikumar, K.; Jayathirtha Rao, V. Baylis–Hillman adducts between pyridine carboxaldehyde derivatives and cyclic enones. *Tetrahedron* **2006a**, *62*, 954–959.
- Narender, P.; Srinivas, U.; Ravinder, M.; Anand Rao, B.; Ramesh, Ch.; Harakishore, K.; Gangadasu, B.; Murthy, U. S. N.; Jayathirtha Rao, V. Synthesis of multisubstituted quinolines from Baylis–Hillman adducts obtained from substituted 2-chloronicotinaldehydes and their antimicrobial activity. *Bioorg. Med. Chem.* **2006b**, *14*, 4600–4609.
- Narender, P.; Ravinder, M.; Sadhu, P. S.; China Raju, B.; Ramesh, Ch.; Jayathirtha Rao, V. Synthesis of substituted 1,8-naphthyridine-3-carboxylates from Baylis–Hillman adducts of substituted 2-chloronicotinaldehydes. *Helv. Chim. Acta* **2009**, *92*, 959–966.
- Natarajan, J. K.; Alumasa, J. N.; Yearick, K.; Ekoue-Kovi, K. A.; Casabianca, L. B.; de Dios, A. C.; Wolf, C.; Roepe, P. D. 4-*N*-, 4-*S*-, and 4-*O*-chloroquine analogues: influence of side chain length and quinolyl nitrogen  $pK_a$  on activity vs chloroquine resistant malaria. *J. Med. Chem.* **2008**, *51*, 3466–3479.
- Ravinder, M.; Sadhu, P. S.; Jayathirtha Rao, V. Simple, facile and one-pot conversion of the Baylis–Hillman acetates into 3,5,6-trisubstituted-2-pyridones. *Tetrahedron Lett.* **2009**, *50*, 4229–4232.
- Ravinder, M.; Sadhu, P. S.; Santhoshi, A.; Narender, P.; Swamy, G. Y. S. K.; Ravi Kumar, K.; Jayathirtha Rao, V. Synthesis of new aminonicotinate derivatives from acetylated Baylis–Hillman adducts and enamino esters via a consecutive [3+3]-annulation protocol. *Synthesis* **2010**, *41*, 573–578.
- Roth, H. J.; Kleemann, A. *Pharmaceutical Chemistry. Drug Synthesis*; Prentice Hall Europe: London, **1988**.
- Sheldrick, G. M. A short history of *SHELX*. *Acta Crystallogr* **2008**, *A64*, 112–122.
- Srinivas, C.; Kumar, Ch. N. S. S. P.; China Raju, B.; Jayathirtha Rao, V.; Naidu, V. G. M.; Ramakrishna, S.; Diwan, P. V. First stereoselective total synthesis and anticancer activity of new amide alkaloids of roots of pepper. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 5915–5918.
- Suryawanshi, S. N.; Chandra, N.; Kumar, P.; Porwal, J.; Gupta, S. Chemotherapy of leishmaniasis Part-VIII: synthesis and



- bioevaluation of novel chalcones. *Eur. J. Med. Chem.* **2008**, *43*, 2473–2478.
- Tomar, V.; Bhattacharjee, G.; Kamaluddin, Rajakumar, S.; Srivastava, K.; Puri, S. K. Synthesis of new chalcone derivatives containing acridinyl moiety with potential antimalarial activity. *Eur. J. Med. Chem.* **2010**, *45*, 745–751.
- Trager, W.; Jensen, J. B. Human malaria parasite in continuous culture. *Science* **1976**, *193*, 673–675.
- Venkatesan, P.; Sumathi, S. Piperidine mediated synthesis of *N*-heterocyclic chalcones and their antibacterial activity. *J. Heterocycl. Chem.* **2010**, *47*, 81–84.
- Vlahov, R.; Parushev, St.; Vlahov, J.; Nickel, P.; Snatzke, G. Synthesis of some new quinoline derivatives – potential antimalarial drugs. *Pure Appl. Chem.* **1990**, *62*, 1303–1306.

Received May 23, 2011; accepted June 27, 2011